Literature DB >> 19717020

Joint Commission primary stroke center certification does not affect proband enrollment: the siblings with ischemic stroke study.

Alexa N Richie1, Jorge Trejo, Christian G Bowers, Rebecca B McNeil, Dale M Gamble, Sothear H Luke, Robert D Brown, Thomas G Brott, Brett M Kissela, Bradford B Worrall, James F Meschia.   

Abstract

BACKGROUND: The Joint Commission (JC) certifies primary stroke centers in the United States. Whether certification promotes enrollment of study subjects into stroke research studies is not known. We examined whether enrollment performance of centers was related to JC certification status.
METHODS: The 51 US Siblings with Ischemic Stroke Study (SWISS) centers were characterized by JC certification status, year of certification, year initiated into SWISS, center location, and whether the center had a vascular/stroke neurology fellowship program accredited by the Accreditation Council for Graduate Medical Education. Performance measures included days elapsed from initiation to first enrollment, total enrollments within 12 months after initiation, and annual rate of enrollment thereafter.
RESULTS: In all, 36 of 51 SWISS sites (71%) were JC certified. A total of 32 (63%) were initiated into the study from 2000 through 2002, and 19 (37%) were initiated from 2005 through May 2008. Comparison of certified and noncertified sites showed no significant difference in the time to first enrollment (median, 77.5 v 115 days; P = .90), total enrollees in the first year (median, 3 v 2 probands; P = .69), or annual enrollment rate (median, 1.9 v 1.8 probands; P = .72). The rate of enrollment or time to first enrollment was not different between 2000-to-2002 and 2005-to-2008 sites. Early-initiated centers tended to have better year-1 enrollment than later-initiated centers (3 v 2 probands; P = .056).
CONCLUSIONS: JC certification did not have a significant effect on SWISS center enrollment. The JC should encourage the research mission among certified stroke centers.

Entities:  

Mesh:

Year:  2009        PMID: 19717020      PMCID: PMC2748667          DOI: 10.1016/j.jstrokecerebrovasdis.2009.01.005

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  10 in total

1.  Recruiting subjects for acute stroke trials: a meta-analysis.

Authors:  Jacob S Elkins; Talayeh Khatabi; Lawrence Fung; John Rootenberg; S Claiborne Johnston
Journal:  Stroke       Date:  2005-12-01       Impact factor: 7.914

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  Trends in acute ischemic stroke trials through the 20th century.

Authors:  C S Kidwell; D S Liebeskind; S Starkman; J L Saver
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

Review 4.  Ethical and methodological issues in pedigree stroke research.

Authors:  B B Worrall; D T Chen; J F Meschia
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

Review 5.  Recommendations for the establishment of primary stroke centers. Brain Attack Coalition.

Authors:  M J Alberts; G Hademenos; R E Latchaw; A Jagoda; J R Marler; M R Mayberg; R D Starke; H W Todd; K M Viste; M Girgus; T Shephard; M Emr; P Shwayder; M D Walker
Journal:  JAMA       Date:  2000-06-21       Impact factor: 56.272

6.  Establishment of primary stroke centers: a survey of physician attitudes and hospital resources.

Authors:  C S Kidwell; T Shephard; S Tonn; B Lawyer; M Murdock; W Koroshetz; M Alberts; G J Hademenos; J L Saver
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

7.  Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.

Authors:  Susan Unipan Lattimore; Julio Chalela; Lisa Davis; Thomas DeGraba; Mustapha Ezzeddine; Joseph Haymore; Paul Nyquist; Alison E Baird; John Hallenbeck; Steven Warach
Journal:  Stroke       Date:  2003-05-15       Impact factor: 7.914

8.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Authors:  Ralph L Sacco; Hans-Christoph Diener; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam Vandermaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  The Siblings With Ischemic Stroke Study (SWISS) protocol.

Authors:  James F Meschia; Robert D Brown; Thomas G Brott; Felix E Chukwudelunzu; John Hardy; Stephen S Rich
Journal:  BMC Med Genet       Date:  2002-02-12       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.